MedTrace Logo

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

NCT05778786 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2024-07-17

Study results available
· View outcomes & findings →

Summary

This will be a 4-visit, randomized, controlled, single-masked, bilateral wear, dispensing, 2-treatment, 2-sequence, 2-period crossover study.

Conditions

  • Visual Acuity

Interventions

DEVICE

Acuvue Oasys 1 Day for Astigmatism

CONTROL

DEVICE

TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore

TEST

Sponsors & Collaborators

  • Johnson & Johnson Vision Care, Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Vision Care, Inc. Clinical Trial · Johnson & Johnson Vision Care, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2023-05-24
Completion
2023-05-24
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05778786 on ClinicalTrials.gov